Overview

An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis

Status:
Completed
Trial end date:
2021-07-27
Target enrollment:
Participant gender:
Summary
The main objectives of this trial are to evaluate the long term efficacy and safety of different doses of BI 655064 versus placebo as add-on therapy to Standard of Care (SOC) during maintenance therapy for lupus nephritis.
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim